A Phase I/IIA Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients With Advanced Solid Malignancies (FAK-PD1)

Trial Profile

A Phase I/IIA Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients With Advanced Solid Malignancies (FAK-PD1)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Defactinib (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 30 May 2017 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
    • 30 May 2017 Planned primary completion date changed from 1 Jun 2018 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top